This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Stereotaxis Announces Positive Results From First 50 Clinical Procedures Performed With New Niobe ES™ System

Stock quotes in this article: STXS





 

 

ST. LOUIS, Jan. 10, 2012 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ: STXS) today announced the completion of the first 50 clinical procedures using the Company's new Niobe ES™ system to treat patients with a variety of complex cardiac arrhythmias.  A majority of the first 50 cases were performed to treat atrial fibrillation (AF), the most common type of cardiac arrhythmia(1).  Positive initial results with the Niobe ES system in Europe demonstrate that the average time for completion of mapping and ablation for the initial AF patients was 69 minutes.  The data will be featured at the Boston Atrial Fibrillation Symposium 2012 to be held on January 12-14, 2012.

The Epoch™ platform, which encompasses the Niobe ES system, is the Company's new generation comprehensive solution for the electrophysiology (EP) laboratory. It is designed to improve efficiency with a fully-remote, networked and modular robotic, magnetic system that enables greater surgical precision and improved catheter control while reducing the risk of complications.  Stereotaxis began initial shipments of the Epoch platform in mid-December 2011, including six system upgrades from the Niobe ® II navigation system at leading medical centers in the United States and Europe. 

Professor Carlo Pappone of Villa Maria Cecilia Hospital, Cotignola Italy, said, "My vision was to click on the map and for the catheter to quickly and precisely move to that spot.  Today with the Epoch platform, this is a reality.  I believe the Epoch platform is one of the most important innovations for the EP practice to date.  With the Epoch technology all physicians can successfully and consistently perform high quality AF procedures with the assurance of superior patient care."

THE HEART HOSPITAL Baylor Plano in Plano, Texas was the first North American site to install the new Epoch platform, and the first hospital in the world to perform an EP procedure using the new system.

"Interventional physicians want to leverage advanced technology that minimizes surgical risks to the patient while increasing the likelihood of a favorable outcome," said Brian DeVille, M.D., FACC, eletrophysiologist on the medical staff at THE HEART HOSPITAL Baylor Plano.  "The new Niobe ES system will enable electrophysiologists on the medical staff to deliver therapy in a precise manner, while reducing X-ray exposure and procedure time for our patients."

"The initial feedback and interest in our new Epoch platform has been very favorable," said Michael P. Kaminski, President and CEO of Stereotaxis.  "We look forward to continuing to build on the momentum of this milestone and have commitments for 12 additional system upgrades to Niobe ES which will be installed over the next few months."

About Stereotaxis             www.stereotaxis.com          www.odysseyexperience.com

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe ® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation and reduced x-ray exposure.



1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,734.67 -70.04 -0.42%
S&P 500 1,938.49 -7.67 -0.39%
NASDAQ 4,400.0580 -22.0270 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs